Document is current
Any future updates will be listed below
-
Authors
Morris, Laurel S. https://orcid.org/0000-0002-5862-6650
Costi, Sara
Hameed, Sara
Collins, Katherine A.
Stern, Emily R.
Chowdhury, Avijit
Morel, Carole https://orcid.org/0000-0002-5076-1938
Salas, Ramiro https://orcid.org/0000-0002-1105-566X
Iosifescu, Dan V.
Han, Ming-Hu
Mathew, Sanjay J. https://orcid.org/0000-0002-2715-6641
Murrough, James W. https://orcid.org/0000-0001-6286-1242
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R61MH111932)
- License Information
-
More Information
Article History
Received: 6 July 2024
Revised: 13 February 2025
Accepted: 14 March 2025
First Online: 25 March 2025
Competing interests
: Dr. Costi has provided consultation services for Boehringer Ingelheim, Guidepoint and TCG Crossover. In the last 10 years, Dr. Iosifescu has served as a consultant for Alkermes, Allergan, Angelini, Autobahn, Axsome, Biogen, Boehringer Ingelheim, the Centers for Psychiatric Excellence, Clexio, Delix, Jazz, LivaNova, Lundbeck, Neumora, Otsuka, Precision Neuroscience, Relmada, Sage, and Sunovion. He has received grant support (paid to his institutions) from Alkermes, AstraZeneca, BrainsWay, LiteCure, NeoSync, Otsuka, Roche, and Shire. In the past 24 months, Dr. Murrough has provided consultation services for LivaNova, KetaMed, Inc, Merk, Cliniclabs, Inc., Biohaven Pharmaceuticals, Inc., Compass Pathfinder, Xenon Pharmaceuticals, and Clexio Biosciences. Drs. Murrough and Han are named on a patent pending for the use of KCNQ channel openers to treat depression and related conditions. Dr. Collins has consulted for MedAvante-ProPhase, and A. Stein- Regulatory Affairs Consulting, Ltd. in the past, and currently serves as a consultant to Cronos Clinical Consulting Services, Inc. and Relmada Therapeutics, Inc. Dr. Mathew has received consultant fees from Abbott, Almatica Pharma, Beckley Psytech, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Brii Biosciences, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Engrail Therapeutics, Freedom Biosciences, Liva Nova, Levo Therapeutics, Merck, Motif Neurotech, Neumora, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion Pharmaceuticals, Xenon Pharmaceuticals, Worldwide Clinical Trials, and XW Pharma. Dr. Mathew has received research support from Boehringer-Ingelheim, Engrail Therapeutics, Merck, Neurocrine, and Sage Therapeutics. Dr. Han is supported by the National Key R&D Program of China (Grant Nos. 2021ZD0202900 and 2021ZD0202902), Research Fund for International Senior Scientists (Grant No. T2250710685), Shenzhen Natural Science Foundation (Grant No. JCYJ20220818101600001), Shenzhen Key Laboratory of Precision Diagnosis and Treatment of Depression (Grant No. ZDSYS20220606100606014), Shenzhen Medical Research Fund (Grant No. SMRF B2303012), and Science and Technology Research and Development Foundation of Shenzhen (High-level Talent Innovation and Entrepreneurship Plan of Shenzhen Team Funding) (Grant No. KQTD20221101093608028). The other authors declare no other disclosures.
